CYYN.F Stock Overview
Cynata Therapeutics Limited, together with its subsidiaries, develops and commercializes proprietary induced pluripotent stem cell and mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Cynata Therapeutics Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.11 |
| 52 Week High | AU$0.11 |
| 52 Week Low | AU$0.072 |
| Beta | 0.81 |
| 1 Month Change | n/a |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | -86.42% |
| Change since IPO | -86.25% |
Recent News & Updates
Recent updates
Shareholder Returns
| CYYN.F | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | 1.0% | 1.2% |
| 1Y | n/a | 0.7% | 24.9% |
Return vs Industry: Insufficient data to determine how CYYN.F performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how CYYN.F performed against the US Market.
Price Volatility
| CYYN.F volatility | |
|---|---|
| CYYN.F Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: CYYN.F has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine CYYN.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | n/a | Kilian Kelly | www.cynata.com |
Cynata Therapeutics Limited, together with its subsidiaries, develops and commercializes proprietary induced pluripotent stem cell and mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia. The company’s lead therapeutic product candidate is CYP-001, which has completed Phase I clinical trial for the treatment of graft versus host disease. It also develops CYP-004, which is in Phase III clinical trial used for the treatment of osteoarthritis; and CYP-006TK, a novel polymercoated silicon wound dressing for diabetic wounds.
Cynata Therapeutics Limited Fundamentals Summary
| CYYN.F fundamental statistics | |
|---|---|
| Market cap | US$23.35m |
| Earnings (TTM) | -US$8.87m |
| Revenue (TTM) | US$1.56m |
15.7x
P/S Ratio-2.8x
P/E RatioIs CYYN.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CYYN.F income statement (TTM) | |
|---|---|
| Revenue | AU$2.40m |
| Cost of Revenue | AU$0 |
| Gross Profit | AU$2.40m |
| Other Expenses | AU$16.04m |
| Earnings | -AU$13.65m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.076 |
| Gross Margin | 100.00% |
| Net Profit Margin | -568.80% |
| Debt/Equity Ratio | 0% |
How did CYYN.F perform over the long term?
See historical performance and comparison